# US 2024/0392035 A1 · Engineered anti-her2 bispecific proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392035 A1
- Document ID: US20240392035A1
- Status: Published application
- Kind: A1
- Application number: 18/685,583
- Filed: 2022-08-25
- Published: 2024-11-28
- Earliest claimed: 2021-08-25
- Assignees: Denali Therapeutics Inc.
- Applicants: Denali Therapeutics Inc.
- Inventors: Abira BANDYOPADHYAY; Allisa Jayne CLEMENS; Do Jin KIM; Michelle E. PIZZO; Lu SHAN; Richard THÉOLIS, Jr.; Raymond Ka Hang TONG
- Web page: https://patentgrep.com/patent/US20240392035A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

In one aspect, bispecific proteins having the ability to specifically bind to both subdomain II of human HER2 and subdomain IV of human HER2 are provided. In another aspect, methods of treating a cancer or treating brain metastasis of a cancer using a bispecific protein that specifically binds to subdomain II and subdomain IV of human HER2 are provided.

## Claims

### Claim 1

A protein comprising:
(a) a first Fc polypeptide that is fused at the N-terminus to an Fd portion of a Fab;
(b) a second Fc polypeptide that is fused at the N-terminus to a single-chain variable fragment (scFv), wherein the first and second Fc polypeptides form an Fc dimer; and
(c) a light chain polypeptide that pairs with the Fd portion recited in (a) to form a Fab,
wherein the Fab binds to subdomain II of human HER2 and the scFv binds to subdomain IV of human HER2, or wherein the Fab binds to subdomain IV of human HER2 and the scFv binds to subdomain II of human HER2, and
wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises a S239D and/or a I332E substitution, according to EU numbering.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprising the S239D and/or the I332E substitution is capable of enhancing HER2-mediated effector function.

### Claim 3 (depends on 1)

The protein of claim 1, wherein:
(a) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(b) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(d) the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(f) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(g) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(h) the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(i) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(j) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(k) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(l) the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(m) the first Fc polypeptide comprises a S239D substitution, according to EU numbering;
(n) the first Fc polypeptide comprises a I332E substitution, according to EU numbering; or
(o) the first Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering.

### Claim 4 (depends on 3)

The protein of claim 3, wherein:
(a) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(b) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(d) the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering; or
(f) the first Fc polypeptide comprises a I332E substitution, according to EU numbering.

### Claim 5 (depends on 4)

The protein of claim 4, wherein:
(a) the first Fc polypeptide comprises a I332E substitution and a serine at position 239, and the second Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, according to EU numbering;
(b) the first Fc polypeptide comprises a S239D and a I332E substitution, and the second Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, and the second Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering;
(d) the first Fc polypeptide comprises a serine at position 239 and a isoleucine at 332, and the second Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering; or
(f) the first Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering, and the second Fc polypeptide comprises a serine at position 239 and a isoleucine at 332.

### Claim 6 (depends on 1)

The protein of claim 1, wherein the Fab binds to subdomain II of human HER2 and the scFv binds to subdomain IV of human HER2.

### Claim 7 (depends on 1)

The protein of claim 1, wherein the Fab binds to subdomain IV of human HER2 and the scFv binds to subdomain II of human HER2.

### Claim 8 (depends on 1)

The protein of claim 1, wherein the second Fc polypeptide is fused to the scFv via a first linker.

### Claim 9 (depends on 8)

The protein of claim 8, wherein the first linker has a length from 1 to 20 amino acids.

### Claim 10 (depends on 8)

The protein of claim 8, wherein the first linker comprises a sequence of any one of GGSGGGSGGGSGGGSGGGSG (SEQ ID NO:116; (GGSG)5), GGGGS (SEQ ID NO:117; G4S), GGGGSGGGGS (SEQ ID NO:118; (G4S)2), GGGGSGGGGSGGGGS (SEQ ID NO:119; (G4S)3), GGGGSGGGGSGGGG (SEQ ID NO:120; (G4S)2-G4), GGGGSGGGGSGG (SEQ ID NO:121), GGGGGSGGGGS (SEQ ID NO:122), and GGGGGSGGGGGSGGGGS (SEQ ID NO:123).

### Claim 11 (depends on 1)

The protein of claim 1, wherein the scFv comprises a VL region and a VH region that are connected via a second linker.

### Claim 12 (depends on 11)

The protein of claim 11, wherein the second linker has a length from 1 to 20 amino acids.

### Claim 13 (depends on 11)

The protein of claim 11, wherein the second linker comprises a sequence of any one of GGSGGGSGGGSGGGSGGGSG (SEQ ID NO:116; (GGSG)5), GGGGS (SEQ ID NO:117; G4S), GGGGSGGGGS (SEQ ID NO:118; (G4S)2), GGGGSGGGGSGGGGS (SEQ ID NO:119; (G4S)3), GGGGSGGGGSGGGG (SEQ ID NO:120; (G4S)2-G4), GGGGSGGGGSGG (SEQ ID NO:121), GGGGGSGGGGS (SEQ ID NO:122), and GGGGGSGGGGGSGGGGS (SEQ ID NO:123).

### Claim 14 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide and/or the second Fc polypeptide specifically binds to a transferrin receptor (TfR).

### Claim 15 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide and the second Fc polypeptide each comprises modifications that promote heterodimerization.

### Claim 16 (depends on 15)

The protein of claim 15, wherein the first Fc polypeptide comprises a T366W substitution and the second Fc polypeptide comprises T366S, L368A, and Y407V substitutions, according to EU numbering.

### Claim 17 (depends on 15)

The protein of claim 15, wherein the first Fc polypeptide comprises T366S, L368A, and Y407V substitutions and the second Fc polypeptide comprises a T366W substitution, according to EU numbering.

### Claim 18 (depends on 14)

The protein of claim 14, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises modifications that reduce TfR-mediated effector function.

### Claim 19 (depends on 18)

The protein of claim 18, wherein the modifications that reduce effector function are L234A and L235A substitutions, according to EU numbering.

### Claim 20 (depends on 19)

The protein of claim 19, wherein the first Fc polypeptide specifically binds to TfR and comprises L234A and L235A substitutions.

### Claim 21 (depends on 20)

The protein of claim 20, wherein the first Fc polypeptide further comprises a P329G or a P329S substitution, according to EU numbering.

### Claim 22 (depends on 21)

The protein of claim 21, wherein the second Fc polypeptide comprises Leu at positions 234 and 235 and a proline at position 329, according to EU numbering.

### Claim 23 (depends on 19)

The protein of claim 19, wherein the second Fc polypeptide specifically binds to TfR and comprises L234A and L235A substitutions.

### Claim 24 (depends on 23)

The protein of claim 23, wherein the second Fc polypeptide further comprises a P329G or a P329S substitution, according to EU numbering.

### Claim 25 (depends on 24)

The protein of claim 24, wherein the first Fc polypeptide comprises Leu at positions 234 and 235 and a proline at position 329, according to EU numbering.

### Claim 26 (depends on 1)

The protein of claim 1, wherein a hinge region or a portion thereof is linked to the N-terminus of the first Fc polypeptide and/or the second Fc polypeptide.

### Claim 27 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:131-149 and 183-196.

### Claim 28 (depends on 27)

The protein of claim 27, wherein the first Fc polypeptide or the second Fc polypeptide comprises a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:133 and 183-185.

### Claim 29 (depends on 27)

The protein of claim 27, wherein the first Fc polypeptide or the second Fc polypeptide comprises a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:137 and 186-196.

### Claim 30 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:135-139 and 186-196.

### Claim 31 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide comprises Ala at position 234, Ala at position 235, Trp at position 366, Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:137, and
the second Fc polypeptide comprises Ser at position 366, Ala at position 368, and Val at position 407, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:133.

### Claim 32 (depends on 1)

The protein of claim 1, wherein the first Fc polypeptide comprises Ser at position 366, Ala at position 368, and Val at position 407, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:133, and
the second Fc polypeptide comprises Ala at position 234, Ala at position 235, Trp at position 366, Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:137.

### Claim 33

A protein comprising:
(a) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:1, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:159, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(b) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 164, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:173, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(c) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 164, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:174, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(d) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 166, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:173, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(e) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 165, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:173, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(f) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 165, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:174, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(g) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 167, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:173, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(h) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 164, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:175, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(i) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 164, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:176, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(j) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 166, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:175, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(k) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 165, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:175, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(l) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 165, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:176, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25; or
(m) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 167, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:175, and (iii) a light chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:25.

### Claim 34 (depends on 33)

The protein of claim 33, wherein:
(a) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:1, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:159, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(b) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:164, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:173, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(c) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:164, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:174, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(d) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:166, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:173, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(e) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:165, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO: 173, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(f) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:165, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:174, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(g) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:167, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:173, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(h) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:164, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:175, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(i) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:164, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:176, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(j) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:166, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:175, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(k) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:165, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:175, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(l) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:165, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:176, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25; or
(m) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:167, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:175, and (iii) the light chain polypeptide comprises the sequence of SEQ ID NO:25.

### Claim 35

A protein comprising:
(a) a first Fc polypeptide that is fused at the N-terminus to an Fd portion of a Fab;
(b) a second Fc polypeptide that is fused at the N-terminus to an Fd portion of a Fab, wherein the first and second Fc polypeptides form an Fc dimer; and
(c) two light chain polypeptides that each pairs with each Fd portion recited in (a) and (b) to form a Fab,
wherein the Fd portion in (a) and/or (b) is fused at the N-terminus to an scFv,
wherein the Fab binds to subdomain II of human HER2 and the scFv binds to subdomain IV of human HER2, or wherein the Fab binds to subdomain IV of human HER2 and the scFv binds to subdomain II of human HER2, and
wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises a S239D and/or a I332E substitution, according to EU numbering.

### Claim 36 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprising the S239D and/or the I332E substitution is capable of enhancing HER2-mediated effector function.

### Claim 37 (depends on 35)

The protein of claim 35, wherein:
(a) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(b) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(d) the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(f) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(g) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(h) the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(i) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(j) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(k) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(l) the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering;
(m) the first Fc polypeptide comprises a S239D substitution, according to EU numbering;
(n) the first Fc polypeptide comprises a I332E substitution, according to EU numbering; or
(o) the first Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering.

### Claim 38 (depends on 37)

The protein of claim 37, wherein:
(a) the first Fc polypeptide comprises a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(b) the first Fc polypeptide comprises a S239D and a I332E substitution and the second Fc polypeptide comprises a S239D substitution, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(d) the second Fc polypeptide comprises a I332E substitution, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering; or
(f) the first Fc polypeptide comprises a I332E substitution, according to EU numbering.

### Claim 39 (depends on 38)

The protein of claim 38, wherein:
(a) the first Fc polypeptide comprises a I332E substitution and a serine at position 239, and the second Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, according to EU numbering;
(b) the first Fc polypeptide comprises a S239D and a I332E substitution, and the second Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, according to EU numbering;
(c) the first Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, and the second Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering;
(d) the first Fc polypeptide comprises a serine at position 239 and a isoleucine at position 332, and the second Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering;
(e) the first Fc polypeptide comprises a S239D substitution and a isoleucine at position 332, and the second Fc polypeptide comprises a S239D and a I332E substitution, according to EU numbering; or
(f) the first Fc polypeptide comprises a I332E substitution and a serine at position 239, according to EU numbering, and the second Fc polypeptide comprises a serine at position 239 and a isoleucine at position 332.

### Claim 40 (depends on 35)

The protein of claim 35, wherein the Fab binds to subdomain II of human HER2 and the scFv binds to subdomain IV of human HER2.

### Claim 41 (depends on 35)

The protein of claim 35, wherein the Fab binds to subdomain IV of human HER2 and the scFv binds to subdomain II of human HER2.

### Claim 42 (depends on 35)

The protein of claim 35, wherein the Fd portion in (a) or (b) is fused at the N-terminus to the scFv.

### Claim 43 (depends on 35)

The protein of claim 35, wherein the Fd portion in (a) and/or (b) is fused to the scFv via a first linker.

### Claim 44 (depends on 43)

The protein of claim 43, wherein the first linker has a length from 1 to 20 amino acids.

### Claim 45 (depends on 43)

The protein of claim 43, wherein the first linker comprises a sequence of any one of GGSGGGSGGGSGGGSGGGSG (SEQ ID NO:116; (GGSG)5), GGGGS (SEQ ID NO:117; G4S), GGGGSGGGGS (SEQ ID NO:118; (G4S)2), GGGGSGGGGSGGGGS (SEQ ID NO:119; (G4S)3), GGGGSGGGGSGGGG (SEQ ID NO:120; (G4S)2-G4), GGGGSGGGGSGG (SEQ ID NO:121), GGGGGSGGGGS (SEQ ID NO:122), and GGGGGSGGGGGSGGGGS (SEQ ID NO:123).

### Claim 46 (depends on 35)

The protein of claim 35, wherein the scFv comprises a VL region and a VH region that are connected via a second linker.

### Claim 47 (depends on 46)

The protein of claim 46, wherein the second linker has a length from 1 to 20 amino acids.

### Claim 48 (depends on 46)

The protein of claim 46, wherein the second linker comprises a sequence of any one of GGSGGGSGGGSGGGSGGGSG (SEQ ID NO:116; (GGSG)5), GGGGS (SEQ ID NO:117; G4S), GGGGSGGGGS (SEQ ID NO:118; (G4S)2), GGGGSGGGGSGGGGS (SEQ ID NO:119; (G4S)3), GGGGSGGGGSGGGG (SEQ ID NO:120; (G4S)2-G4), GGGGSGGGGSGG (SEQ ID NO:121), GGGGGSGGGGS (SEQ ID NO:122), and GGGGGSGGGGGSGGGGS (SEQ ID NO:123).

### Claim 49 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide and/or the second Fc polypeptide specifically binds to a transferrin receptor (TfR).

### Claim 50 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide and the second Fc polypeptide each comprises modifications that promote heterodimerization.

### Claim 51 (depends on 50)

The protein of claim 50, wherein the first Fc polypeptide comprises a T366W substitution and the second Fc polypeptide comprises T366S, L368A, and Y407V substitutions, according to EU numbering.

### Claim 52 (depends on 50)

The protein of claim 50, wherein the first Fc polypeptide comprises T366S, L368A, and Y407V substitutions and the second Fc polypeptide comprises a T366W substitution, according to EU numbering.

### Claim 53 (depends on 49)

The protein of claim 49, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises modifications that reduce TfR-mediated effector function.

### Claim 54 (depends on 53)

The protein of claim 53, wherein the modifications that reduce effector function are L234A and L235A substitutions, according to EU numbering.

### Claim 55 (depends on 54)

The protein of claim 54, wherein the first Fc polypeptide specifically binds to TfR and comprises L234A and L235A substitutions.

### Claim 56 (depends on 55)

The protein of claim 55, wherein the first Fc polypeptide further comprises a P329G or a P329S substitution, according to EU numbering.

### Claim 57 (depends on 56)

The protein of claim 56, wherein the second Fc polypeptide comprises Leu at positions 234 and 235 and proline at position 329, according to EU numbering.

### Claim 58 (depends on 54)

The protein of claim 54, wherein the second Fc polypeptide specifically binds to TfR and comprises L234A and L235A substitutions.

### Claim 59 (depends on 58)

The protein of claim 58, wherein the second Fc polypeptide further comprises a P329G or a P329S substitution, according to EU numbering.

### Claim 60 (depends on 59)

The protein of claim 59, wherein the first Fc polypeptide comprises Leu at positions 234 and 235 and proline at position 329, according to EU numbering.

### Claim 61 (depends on 35)

The protein of claim 35, wherein a hinge region or a portion thereof is linked to the N-terminus of the first Fc polypeptide and/or the second Fc polypeptide.

### Claim 62 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:131-149 and 183-196.

### Claim 63 (depends on 62)

The protein of claim 62, wherein the first Fc polypeptide or the second Fc polypeptide comprises a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:133 and 183-185.

### Claim 64 (depends on 62)

The protein of claim 62, wherein the first Fc polypeptide or the second Fc polypeptide comprises a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:137 and 186-196.

### Claim 65 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide and/or the second Fc polypeptide independently comprises Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to a sequence selected from SEQ ID NOS:135-139 and 186-196.

### Claim 66 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide comprises Ala at position 234, Ala at position 235, Trp at position 366, Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:137, and
the second Fc polypeptide comprises Ser at position 366, Ala at position 368, and Val at position 407, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:133.

### Claim 67 (depends on 35)

The protein of claim 35, wherein the first Fc polypeptide comprises Ser at position 366, Ala at position 368, and Val at position 407, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:133, and
the second Fc polypeptide comprises Ala at position 234, Ala at position 235, Trp at position 366, Tyr at position 384, Thr at position 386, Glu at position 387, Trp at position 388, Ser at position 389, Ser at position 413, Glu at position 415, Glu at position 416, and Phe at position 421, according to EU numbering, and a sequence having at least 90% identity to the sequence of SEQ ID NO:137.

### Claim 68

A protein comprising:
(a) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:6, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:160, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(b) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:6, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:161, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(c) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:6, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:162, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(d) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:177, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(e) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:178, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(f) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 171, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:177, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(g) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:177, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(h) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:178, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(i) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 172, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:177, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(j) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:179, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(k) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:180, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(l) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 171, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:179, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(m) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:179, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(n) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:180, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(o) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 172, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:179, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(p) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:181, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(q) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 169, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:182, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(r) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 171, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:181, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(s) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:181, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(t) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 170, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:182, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26; or
(u) (i) a first heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO: 172, (ii) a second heavy chain polypeptide comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:181, and (iii) two light chain polypeptides each comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:26.

### Claim 69 (depends on 68)

The protein of claim 68, wherein:
(a) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:6, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:160, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(b) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:6, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:161, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(c) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:6, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO: 162, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(d) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:177, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(e) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:178, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(f) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:171, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:177, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(g) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:177, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(h) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:178, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(i) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:172, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:177, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(j) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:179, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(k) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:180, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(l) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:171, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:179, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(m) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:179, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(n) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:180, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(o) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:172, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:179, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(p) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:181, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(q) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:169, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:182, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(r) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:171, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:181, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(s) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:181, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(t) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:170, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:182, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26; or
(u) (i) the first heavy chain polypeptide comprises the sequence of SEQ ID NO:172, (ii) the second heavy chain polypeptide comprises the sequence of SEQ ID NO:181, and (iii) the two light chain polypeptides each comprises the sequence of SEQ ID NO:26.

### Claim 70 (depends on 1)

A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

### Claim 71 (depends on 1)

An isolated polynucleotide comprising a nucleotide sequence encoding the protein of claim 1.

### Claim 72 (depends on 71)

A vector comprising the polynucleotide of claim 71.

### Claim 73 (depends on 71, 72)

A host cell comprising the polynucleotide of claim 71 or the vector of claim 72.

### Claim 74 (depends on 1, 70)

A method for treating a cancer or treating brain metastasis of a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of claim 1 or the pharmaceutical composition of claim 70.

### Claim 75 (depends on 74)

The method of claim 74, wherein the protein is adminstered in combination with a chemotherapy or radiation therapy.

### Claim 76 (depends on 74)

The method of claim 74, wherein the cancer is a metastatic cancer.

### Claim 77 (depends on 74)

The method of claim 74, wherein the cancer is a breast cancer.

### Claim 78 (depends on 74)

The method of claim 74, wherein the cancer is a HER2-positive cancer.
